GALT - CytoDyn's 13 Shots On Goal De-Risk Investment
CytoDyn's 13 Shots on Goal De-risk's Investment
- 13 disease indications in the pipeline
- First approval possible in 2020 & low risk of drug failure
- Newest player in NASH
- Robust licensing and partnering potential
- Large revenue likely in 2020
CytoDyn Inc. (CYDY), the developer of the CCR5 platform technology, currently has 13 potential indications which can lead to commercialization and revenue. In addition, the company has 6 potential licensing deals which make it an extremely attractive biotech stock on a valuation basis. Potential shareholders who believe that it's a numbers game when it comes